“Both vaccination regimens provide the necessary immune response.
The use of the EpiVacCoron-N vaccine according to the three-dose regimen is intended, first of all, for patients with immune system characteristics, weakened immunity against the background of chronic diseases, ”Vector SSC told RIA Novosti.
Earlier it became known that clinical trials for the vaccine of the Scientific Center "Vector" "EpiVakKorona-N" in people over 60 years of age will begin in February and will last 42 days.
Earlier, the Ministry of Health of Russia issued a permit to the Vector Research Center to conduct clinical trials of the EpiVacCoron-N vaccine in people over 60 years of age.
The end of the tests is scheduled for December 30, 2022.
Epidemiologist, Academician of the Russian Academy of Sciences Gennady Onishchenko, in an interview with NSN, spoke about the importance of revaccination against coronavirus.